5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Permanent O
vision O
loss O
: O
Baseline O
and O
periodic O
vision O
assessment O
is O
required O
( O
5.1 O
) O
* O
Abnormal O
MRI O
signal O
changes O
have O
been O
reported O
in O
some O
infants O
with O
IS O
receiving O
SABRIL O
( O
5.3 O
) O
* O
Suicidal O
behavior O
and O
ideation O
: O
Antiepileptic O
drugs O
, O
including O
SABRIL O
increase O
the O
risk O
of O
suicidal O
thoughts O
and O
behavior O
( O
5.5 O
) O
* O
Withdrawal O
of O
AEDs O
: O
Dose O
should O
be O
tapered O
gradually O
to O
avoid O
withdrawal O
seizures O
( O
5.6 O
) O
* O
Anemia O
: O
Monitor O
for O
symptoms O
of O
anemia O
( O
5.7 O
) O
* O
Somnolence O
and O
fatigue O
: O
Advise O
patients O
not O
to O
drive O
or O
operate O
machinery O
until O
they O
have O
gained O
sufficient O
experience O
on O
SABRIL O
( O
5.8 O
) O
5.1 O
Vision O
Loss O
Because O
of O
the O
risk O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
and O
because O
, O
when O
it O
is O
effective O
, O
SABRIL O
provides O
an O
observable O
symptomatic O
benefit O
, O
patient O
response O
and O
continued O
need O
for O
treatment O
should O
be O
periodically O
assessed O
. O

In O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
should O
be O
withdrawn O
if O
a O
substantial O
clinical O
benefit O
is O
not O
observed O
within O
3 O
months O
of O
initiating O
treatment O
. O

If O
, O
in O
the O
clinical O
judgment O
of O
the O
prescriber O
, O
evidence O
of O
treatment O
failure O
becomes O
obvious O
earlier O
than O
3 O
months O
, O
treatment O
should O
be O
discontinued O
at O
that O
time O
. O

In O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
SABRIL O
should O
be O
withdrawn O
if O
a O
substantial O
clinical O
benefit O
is O
not O
observed O
within O
2 O
to O
4 O
weeks O
. O

If O
, O
in O
the O
clinical O
judgment O
of O
the O
prescriber O
, O
evidence O
of O
treatment O
failure O
becomes O
obvious O
earlier O
than O
2 O
to O
4 O
weeks O
, O
treatment O
should O
be O
discontinued O
at O
that O
time O
[ O
see O
BOXED O
WARNING O
] O
. O

Monitoring O
of O
Vision O
Monitoring O
of O
vision O
by O
an O
ophthalmic O
professional O
with O
expertise O
in O
visual O
field O
interpretation O
and O
the O
ability O
to O
perform O
dilated O
indirect O
ophthalmoscopy O
of O
the O
retina O
is O
required O
, O
unless O
a O
patient O
is O
formally O
exempted O
from O
periodic O
ophthalmologic O
assessment O
as O
documented O
in O
the O
Support O
, O
Help O
And O
Resources O
for O
Epilepsy B-NonOSE_AE
( O
SHARE O
) O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Because O
vision O
testing O
in O
infants O
is O
difficult O
, O
vision B-NonOSE_AE
loss I-NonOSE_AE
may O
not O
be O
detected O
until O
it O
is O
severe O
. O

For O
patients O
receiving O
SABRIL O
who O
are O
not O
exempted O
, O
vision O
assessment O
is O
required O
at O
baseline O
( O
no O
later O
than O
4 O
weeks O
after O
starting O
SABRIL O
) O
and O
at O
least O
every O
3 O
months O
while O
on O
therapy O
and O
about O
3-6 O
months O
after O
the O
discontinuation O
of O
therapy O
. O

The O
diagnostic O
approach O
should O
be O
individualized O
for O
the O
patient O
and O
clinical O
situation O
. O

For O
all O
patients O
, O
attempts O
to O
monitor O
vision O
periodically O
and/or O
formal O
exemptions O
must O
be O
documented O
under O
the O
SHARE O
program O
. O

In O
adults O
and O
cooperative O
pediatric O
patients O
, O
perimetry O
is O
recommended O
, O
preferably O
by O
automated O
threshold O
visual O
field O
testing O
. O

Additional O
testing O
may O
also O
include O
electrophysiology O
( O
e.g. O
, O
electroretinography O
[ O
ERG O
] O
) O
, O
retinal O
imaging O
( O
e.g. O
, O
optical O
coherence O
tomography O
[ O
OCT O
] O
) O
, O
and/or O
other O
methods O
appropriate O
for O
the O
patient O
, O
but O
this O
additional O
testing O
is O
not O
required O
. O

In O
patients O
exempted O
from O
vision O
testing O
, O
treatment O
may O
continue O
according O
to O
clinical O
judgment O
, O
with O
appropriate O
patient O
counseling O
and O
with O
documentation O
in O
the O
SHARE O
program O
of O
the O
exemption O
. O

Because O
of O
variability O
, O
results O
from O
ophthalmic O
monitoring O
must O
be O
interpreted O
with O
caution O
, O
and O
repeat O
assessment O
is O
recommended O
if O
results O
are O
abnormal O
or O
uninterpretable O
. O

Repeat O
assessment O
in O
the O
first O
few O
weeks O
of O
treatment O
is O
recommended O
to O
establish O
if O
, O
and O
to O
what O
degree O
, O
reproducible O
results O
can O
be O
obtained O
, O
and O
to O
guide O
selection O
of O
appropriate O
ongoing O
monitoring O
for O
the O
patient O
. O

The O
onset O
and O
progression O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
SABRIL O
is O
unpredictable O
, O
and O
it O
may O
occur O
or O
worsen O
precipitously O
between O
assessments O
. O

Once O
detected O
, O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
due O
to O
SABRIL O
is O
not O
reversible O
. O

It O
is O
expected O
that O
even O
with O
frequent O
monitoring O
, O
some O
SABRIL O
patients O
will O
develop O
severe O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
. O

Drug O
discontinuation O
should O
be O
considered O
, O
balancing O
benefit O
and O
risk O
, O
if O
visual B-NonOSE_AE
loss I-NonOSE_AE
is O
documented O
. O

5.2 O
SABRIL O
SHARE O
Program O
SABRIL O
is O
available O
only O
through O
a O
restricted O
distribution O
program O
called O
the O
SHARE O
program O
, O
because O
of O
the O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

Notable O
requirements O
components O
of O
the O
SHARE O
Program O
include O
the O
following O
: O
* O
* O
Assess O
vision O
prior O
to O
initiating O
therapy O
and O
then O
every O
3 O
months O
during O
therapy O
. O

* O
Remove O
patients O
from O
SABRIL O
therapy O
if O
the O
patients O
do O
not O
experience O
a O
meaningful O
reduction O
in O
seizures B-Not_AE_Candidate
. O

* O
* O
The O
patient O
is O
blind B-Not_AE_Candidate
( O
subsequent O
Ophthalmologic O
Assessment O
Forms O
do O
not O
need O
to O
be O
submitted O
to O
the O
REMS O
coordinating O
center O
) O
* O
The O
patient O
's O
general O
neurological B-Not_AE_Candidate
and I-Not_AE_Candidate
/ I-Not_AE_Candidate
or I-Not_AE_Candidate
mental I-Not_AE_Candidate
condition I-Not_AE_Candidate
permanently O
precludes O
the O
need O
for O
visual O
assessment O
( O
subsequent O
Ophthalmologic O
Assessment O
Forms O
do O
not O
need O
to O
be O
submitted O
to O
the O
REMS O
coordinating O
center O
) O
* O
The O
patient O
's O
general O
neurological B-Not_AE_Candidate
condition I-Not_AE_Candidate
temporarily O
precludes O
the O
ability O
to O
assess O
visual O
function O
. O

The O
evaluation O
, O
however O
, O
may O
be O
performed O
at O
a O
later O
time O
as O
clinically O
appropriate O
. O

* O
The O
patient O
's O
medical O
condition O
prevents O
visual O
assessment O
being O
performed O
safely O
* O
For O
other O
reasons O
specified O
by O
the O
prescriber O
The O
prescriber O
may O
, O
with O
appropriate O
documentation O
and O
caregiver O
counseling O
, O
exempt O
certain O
patients O
from O
vision O
assessment O
, O
using O
the O
Ophthalmologic O
Assessment O
Form O
, O
if O
: O
Prescribers O
must O
be O
certified O
with O
the O
program O
by O
enrolling O
and O
reviewing O
educational O
materials O
and O
comply O
with O
the O
following O
: O
* O
Patient/parent/legal O
guardian O
must O
understand O
the O
risks O
and O
benefits O
and O
sign O
a O
Patient-Prescriber O
Agreement O
. O

* O
Pharmacies O
that O
dispense O
SABRIL O
must O
be O
certified O
and O
agree O
to O
comply O
with O
the O
REMS O
requirements O
. O

Certified O
pharmacies O
must O
only O
dispense O
SABRIL O
to O
patients O
who O
are O
enrolled O
in O
the O
program O
. O

5.3 O
Magnetic O
Resonance O
Imaging O
( O
MRI O
) O
Abnormalities O
in O
Infants O
Abnormal B-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
characterized O
by O
increased B-OSE_Labeled_AE
T I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
and O
restricted B-OSE_Labeled_AE
diffusion I-OSE_Labeled_AE
in I-OSE_Labeled_AE
a O
symmetric O
pattern O
involving O
the O
thalamus O
, O
basal O
ganglia O
, O
brain O
stem O
, O
and O
cerebellum I-OSE_Labeled_AE
have O
been O
observed O
in O
some O
infants O
treated O
with O
vigabatrin O
for O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
. O

In O
a O
retrospective O
epidemiologic O
study O
in O
infants O
with O
IS B-Not_AE_Candidate
( O
N=205 O
) O
, O
the O
prevalence O
of O
these O
changes O
was O
22 O
% O
in O
vigabatrin O
treated O
patients O
versus O
4 O
% O
in O
patients O
treated O
with O
other O
therapies O
. O

In O
the O
study O
above O
, O
in O
post O
marketing O
experience O
, O
and O
in O
published O
literature O
reports O
, O
these O
changes O
generally O
resolved O
with O
discontinuation O
of O
treatment O
. O

In O
a O
few O
patients O
, O
the O
lesion O
resolved O
despite O
continued O
use O
. O

It O
has O
been O
reported O
that O
some O
infants O
exhibited O
coincident O
motor B-NonOSE_AE
abnormalities I-NonOSE_AE
, O
but O
no O
causal O
relationship O
has O
been O
established O
and O
the O
potential O
for O
long-term O
clinical O
sequelae O
has O
not O
been O
adequately O
studied O
. O

Neurotoxicity B-NonOSE_AE
( O
brain B-NonOSE_AE
histopathology I-NonOSE_AE
and O
neurobehavioral O
abnormalities I-NonOSE_AE
) O
was O
observed O
in O
rats O
exposed O
to O
vigabatrin O
during O
late O
gestation O
and O
the O
neonatal O
and O
juvenile O
periods O
of O
development O
. O

The O
relationship O
between O
these O
findings O
and O
the O
abnormal B-NonOSE_AE
MRI I-NonOSE_AE
findings I-NonOSE_AE
in O
infants O
treated O
with O
vigabatrin O
for O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
is O
unknown O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

The O
specific O
pattern O
of O
signal O
changes O
observed O
in O
IS B-Not_AE_Candidate
patients O
was O
not O
observed O
in O
older O
pediatric O
and O
adult O
patients O
treated O
with O
vigabatrin O
for O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
. O

In O
a O
blinded O
review O
of O
MRI O
images O
obtained O
in O
prospective O
clinical O
trials O
in O
patients O
with O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
3 O
years O
and O
older O
( O
N=656 O
) O
, O
no O
difference O
was O
observed O
in O
anatomic O
distribution O
or O
prevalence O
of O
MRI B-NonOSE_AE
signal I-NonOSE_AE
changes I-NonOSE_AE
between O
vigabatrin O
treated O
and O
placebo O
treated O
patients O
. O

For O
adults O
treated O
with O
SABRIL O
, O
routine O
MRI O
surveillance O
is O
unnecessary O
as O
there O
is O
no O
evidence O
that O
vigabatrin O
causes O
MRI B-NonOSE_AE
changes I-NonOSE_AE
in O
this O
population O
. O

5.4 O
Neurotoxicity O
Vacuolation B-NonOSE_AE
, O
characterized O
by O
fluid O
accumulation O
and O
separation O
of I-NonOSE_AE
the I-NonOSE_AE
outer I-NonOSE_AE
layers I-NonOSE_AE
of I-NonOSE_AE
myelin I-NonOSE_AE
, O
has O
been O
observed O
in I-NonOSE_AE
brain I-NonOSE_AE
white I-NonOSE_AE
matter I-NonOSE_AE
tracts I-NonOSE_AE
in O
adult O
and O
juvenile O
rats O
and O
adult O
mice O
, O
dogs O
, O
and O
possibly O
monkeys O
following O
administration O
of O
vigabatrin O
. O

This O
lesion O
, O
referred O
to O
as O
intramyelinic B-NonOSE_AE
edema I-NonOSE_AE
( O
IME O
) O
, O
was O
seen O
in O
animals O
at O
doses O
within O
the O
human O
therapeutic O
range O
. O

A O
no-effect O
dose O
was O
not O
established O
in O
rodents O
or O
dogs O
. O

In O
the O
rat O
and O
dog O
, O
vacuolation B-NonOSE_AE
was O
reversible O
following O
discontinuation O
of O
vigabatrin O
treatment O
, O
but O
, O
in O
the O
rat O
, O
pathologic O
changes O
consisting O
of O
swollen B-NonOSE_AE
or O
degenerating O
axons I-NonOSE_AE
, O
m O
in I-NonOSE_AE
eralization O
, O
and O
gliosis O
were O
seen O
in O
brain I-NonOSE_AE
areas O
in O
which O
vacuolation B-NonOSE_AE
had O
been O
previously O
observed O
. O

Vacuolation B-NonOSE_AE
in O
adult O
animals O
was O
correlated O
with O
alterations B-NonOSE_AE
in I-NonOSE_AE
MRI I-NonOSE_AE
and O
changes B-NonOSE_AE
in O
visual O
and O
somatosensory I-NonOSE_AE
evoked I-NonOSE_AE
potentials I-NonOSE_AE
( O
EP O
) O
. O

Administration O
of O
vigabatrin O
to O
rats O
during O
the O
neonatal O
and O
juvenile O
periods O
of O
development O
produced O
vacuolar B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
the O
brain O
gray O
matter O
( O
areas O
including O
the O
thalamus O
, O
midbrain O
, O
deep O
cerebellar O
nuclei O
, O
substantia O
nigra O
, O
hippocampus O
, O
and O
forebrain I-NonOSE_AE
) O
which O
are O
considered O
distinct O
from O
the O
IME O
observed O
in O
vigabatrin O
treated O
adult O
animals O
. O

Decreased B-NonOSE_AE
myelination I-NonOSE_AE
and O
evidence O
of O
oligodendrocyte O
in I-NonOSE_AE
jury O
were O
additional O
findings O
in O
the I-NonOSE_AE
brains I-NonOSE_AE
of O
vigabatrin-treated O
rats O
. O

An O
increase B-NonOSE_AE
in I-NonOSE_AE
apoptosis I-NonOSE_AE
was O
seen O
in I-NonOSE_AE
some O
brain I-NonOSE_AE
regions O
following O
vigabatrin O
exposure O
during O
the O
early O
postnatal O
period O
. O

Long-term O
neurobehavioral B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
convulsions B-NonOSE_AE
, O
neuromotor B-NonOSE_AE
impairment I-NonOSE_AE
, O
learning B-NonOSE_AE
deficits I-NonOSE_AE
) O
were O
also O
observed O
following O
vigabatrin O
treatment O
of O
young O
rats O
. O

These O
effects O
in O
young O
animals O
occurred O
at O
doses O
lower O
than O
those O
producing O
neurotoxicity B-NonOSE_AE
in O
adult O
animals O
and O
were O
associated O
with O
plasma O
vigabatrin O
levels O
substantially O
lower O
than O
those O
achieved O
clinically O
in O
infants O
and O
children O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

In O
a O
published O
study O
, O
vigabatrin O
( O
200 O
, O
400 O
mg/kg/day O
) O
induced O
apoptotic B-NonOSE_AE
neurodegeneration I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
brain I-NonOSE_AE
of O
young O
rats O
when O
administered O
by O
intraperitoneal O
injection O
on O
postnatal O
days O
5-7 O
. O

Administration O
of O
vigabatrin O
to O
female O
rats O
during O
pregnancy B-NonOSE_AE
and O
lactation O
at O
doses O
below O
those O
used O
clinically O
resulted O
in O
hippocampal B-NonOSE_AE
vacuolation I-NonOSE_AE
and O
convulsions O
in I-NonOSE_AE
the O
mature O
offspring I-NonOSE_AE
. O

Abnormal B-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
changes O
characterized O
by O
in I-OSE_Labeled_AE
creased O
T2 O
signal O
and O
restricted O
diffusio O
n B-OSE_Labeled_AE
in I-OSE_Labeled_AE
a I-OSE_Labeled_AE
symmetric I-OSE_Labeled_AE
patter I-OSE_Labeled_AE
n O
involving O
the O
thalamus I-OSE_Labeled_AE
, O
basal O
ganglia O
, O
brain O
stem O
, O
and O
cerebellum I-OSE_Labeled_AE
have O
been O
observed O
in O
some O
infants O
treated O
for O
IS B-Not_AE_Candidate
with O
vigabatrin O
. O

Studies O
of O
the O
effects O
of O
vigabatrin O
on O
MRI O
and O
EP O
in O
adult O
epilepsy B-Not_AE_Candidate
patients O
have O
demonstrated O
no O
clear-cut O
abnormalities O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.5 O
Suicidal O
Behavior O
and O
Ideation O
Antiepileptic O
drugs O
( O
AEDs O
) O
, O
including O
SABRIL O
, O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
in O
patients O
taking O
these O
drugs O
for O
any O
indication O
. O

Patients O
treated O
with O
any O
AED O
for O
any O
indication O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Pooled O
analyses O
of O
199 O
placebo-controlled O
clinical O
trials O
( O
mono- O
and O
adjunctive O
therapy O
) O
of O
11 O
different O
AEDs O
showed O
that O
patients O
randomized O
to O
one O
of O
the O
AEDs O
had O
approximately O
twice O
the O
risk O
( O
adjusted O
Relative O
Risk O
1.8 O
, O
95 O
% O
CI O
: O
1.2 O
, O
2.7 O
) O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
compared O
to O
patients O
randomized O
to O
placebo O
. O

In O
these O
trials O
, O
which O
had O
a O
median O
treatment O
duration O
of O
12 O
weeks O
, O
the O
estimated O
incidence O
rate O
of O
suicidal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
ideation O
among O
27,863 O
AED O
treated O
patients O
was O
0.43 O
% O
, O
compared O
to O
0.24 O
% O
among O
16,029 O
placebo O
treated O
patients O
, O
representing O
an O
increase O
of O
approximately O
one O
case O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
for O
every O
530 O
patients O
treated O
. O

There O
were O
four O
suicides B-OSE_Labeled_AE
in O
drug O
treated O
patients O
in O
the O
trials O
and O
none O
in O
placebo O
treated O
patients O
, O
but O
the O
number O
is O
too O
small O
to O
allow O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

The O
increased O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
with O
AEDs O
was O
observed O
as O
early O
as O
one O
week O
after O
starting O
drug O
treatment O
with O
AEDs O
and O
persisted O
for O
the O
duration O
of O
treatment O
assessed O
. O

Because O
most O
trials O
included O
in O
the O
analysis O
did O
not O
extend O
beyond O
24 O
weeks O
, O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
or O
behavior I-NonOSE_AE
beyond O
24 O
weeks O
could O
not O
be O
assessed O
. O

The O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
or O
behavior I-NonOSE_AE
was O
generally O
consistent O
among O
drugs O
in O
the O
data O
analyzed O
. O

The O
finding O
of O
increased O
risk O
with O
AEDs O
of O
varying O
mechanisms O
of O
action O
and O
across O
a O
range O
of O
indications O
suggests O
that O
the O
risk O
applies O
to O
all O
AEDs O
used O
for O
any O
indication O
. O

The O
risk O
did O
not O
vary O
substantially O
by O
age O
( O
5-100 O
years O
) O
in O
the O
clinical O
trials O
analyzed O
. O

Table O
4 O
shows O
absolute O
and O
relative O
risk O
by O
indication O
for O
all O
evaluated O
AEDs O
. O

Table O
4 O
. O

Risk O
by O
Indication O
for O
Antiepileptic O
Drugs O
in O
the O
Pooled O
Analysis O
Indication O
Placebo O
Patients O
with O
Events O
per O
1000 O
Patients O
Drug O
Patients O
with O
Events O
per O
1000 O
Patients O
Relative O
Risk O
: O
Incidence O
of O
Drug O
Events O
in O
Drug O
Patients/Incidence O
in O
Placebo O
Patients O
Risk O
Difference O
: O
Additional O
Drug O
Patients O
with O
Events O
per O
1000 O
Patients O
Epilepsy B-Not_AE_Candidate
1.0 O
3.4 O
3.5 O
2.4 O
Psychiatric B-Not_AE_Candidate
5.7 O
8.5 O
1.5 O
2.9 O
Other O
1.0 O
1.8 O
1.9 O
0.9 O
Total O
2.4 O
4.3 O
1.8 O
1.9 O
The O
relative O
risk O
for O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
was O
higher O
in O
clinical O
trials O
for O
epilepsy B-Not_AE_Candidate
than O
in O
clinical O
trials O
for O
psychiatric O
or O
other O
conditions O
, O
but O
the O
absolute O
risk O
differences O
were O
similar O
for O
the O
epilepsy B-Not_AE_Candidate
and O
psychiatric B-Not_AE_Candidate
indications O
. O

Anyone O
considering O
prescribing O
SABRIL O
or O
any O
other O
AED O
must O
balance O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
with O
the O
risk O
of O
untreated O
illness O
. O

Epilepsy B-Not_AE_Candidate
and O
many O
other O
illnesses O
for O
which O
AEDs O
are O
prescribed O
are O
themselves O
associated O
with O
morbidity O
and O
mortality B-NonOSE_AE
and O
an O
increased O
risk O
of O
suicidal B-Not_AE_Candidate
thoughts I-Not_AE_Candidate
and O
behavior O
. O

Should O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
emerge O
during O
treatment O
, O
the O
prescriber O
needs O
to O
consider O
whether O
the O
emergence O
of O
these O
symptoms O
in O
any O
given O
patient O
may O
be O
related O
to O
the O
illness O
being O
treated O
. O

Patients O
, O
their O
caregivers O
, O
and O
families O
should O
be O
informed O
that O
AEDs O
increase O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
and O
should O
be O
advised O
of O
the O
need O
to O
be O
alert O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
any O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
, O
or O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
behavior O
, O
or O
thoughts B-NonOSE_AE
about I-NonOSE_AE
self I-NonOSE_AE
- I-NonOSE_AE
harm I-NonOSE_AE
. O

Behaviors O
of O
concern O
should O
be O
reported O
immediately O
to O
healthcare O
providers O
. O

5.6 O
Withdrawal O
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
As O
with O
all O
AEDs O
, O
SABRIL O
should O
be O
withdrawn O
gradually O
. O

Patients O
and O
caregivers O
should O
be O
told O
not O
to O
suddenly O
discontinue O
SABRIL O
therapy O
. O

In O
controlled O
clinical O
studies O
in O
adults O
with O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
1000 O
mg/day O
on O
a O
weekly O
basis O
until O
discontinued O
. O

In O
a O
controlled O
study O
in O
pediatric O
patients O
with O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
by O
one O
third O
every O
week O
for O
three O
weeks O
. O

In O
a O
controlled O
clinical O
study O
in O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
at O
a O
rate O
of O
25-50 O
mg/kg O
every O
3-4 O
days O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

5.7 O
Anemia O
In O
North O
American O
controlled O
trials O
in O
adults O
, O
6 O
% O
of O
patients O
( O
16/280 O
) O
receiving O
SABRIL O
and O
2 O
% O
of O
patients O
( O
3/188 O
) O
receiving O
placebo O
had O
adverse O
events O
of O
anemia B-OSE_Labeled_AE
and/or O
met O
criteria O
for O
potentially O
clinically O
important O
hematology B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
involving O
hemoglobin O
, O
hematocrit O
, O
and/or O
RBC O
indices O
. O

Across O
U.S O
. O
controlled O
trials O
, O
there O
were O
mean O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
of O
about O
3 O
% O
and O
0 O
% O
in O
SABRIL O
and O
placebo O
treated O
patients O
, O
respectively O
, O
and O
a O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hematocrit I-OSE_Labeled_AE
of O
about O
1 O
% O
in O
SABRIL O
treated O
patients O
compared O
to O
a O
mean O
gain O
of O
about O
1 O
% O
in O
patients O
treated O
with O
placebo O
. O

In O
controlled O
and O
open O
label O
epilepsy B-Not_AE_Candidate
trials O
in O
adults O
and O
pediatric O
patients O
, O
3 O
SABRIL O
patients O
( O
0.06 O
% O
, O
3/4855 O
) O
discontinued O
for O
anemia B-OSE_Labeled_AE
and O
2 O
SABRIL O
patients O
experienced O
unexplained O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
below O
8 O
g/dL O
and/or O
hematocrit O
below O
24 O
% O
. O

5.8 O
Somnolence O
and O
Fatigue O
SABRIL O
causes O
somnolence B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Patients O
should O
be O
advised O
not O
to O
drive O
a O
car O
or O
operate O
other O
complex O
machinery O
until O
they O
are O
familiar O
with O
the O
effects O
of O
SABRIL O
on O
their O
ability O
to O
perform O
such O
activities O
. O

Pooled O
data O
from O
two O
SABRIL O
controlled O
trials O
in O
adults O
demonstrated O
that O
24 O
% O
( O
54/222 O
) O
of O
SABRIL O
patients O
experienced O
somnolence B-OSE_Labeled_AE
compared O
to O
10 O
% O
( O
14/135 O
) O
of O
placebo O
patients O
. O

In O
those O
same O
studies O
, O
28 O
% O
of O
SABRIL O
patients O
experienced O
fatigue B-OSE_Labeled_AE
compared O
to O
15 O
% O
( O
20/135 O
) O
of O
placebo O
patients O
. O

Almost O
1 O
% O
of O
SABRIL O
patients O
discontinued O
from O
clinical O
trials O
for O
somnolence B-OSE_Labeled_AE
and O
almost O
1 O
% O
discontinued O
for O
fatigue B-OSE_Labeled_AE
. O

Pooled O
data O
from O
three O
SABRIL O
controlled O
trials O
in O
pediatric O
patients O
demonstrated O
that O
6 O
% O
( O
10/165 O
) O
of O
SABRIL O
patients O
experienced O
somnolence B-OSE_Labeled_AE
compared O
to O
5 O
% O
( O
5/104 O
) O
of O
placebo O
patients O
. O

In O
those O
same O
studies O
, O
10 O
% O
( O
17/165 O
) O
of O
SABRIL O
patients O
experienced O
fatigue B-OSE_Labeled_AE
compared O
to O
7 O
% O
( O
7/104 O
) O
of O
placebo O
patients O
. O

No O
SABRIL O
patients O
discontinued O
from O
clinical O
trials O
due O
to O
somnolence B-NonOSE_AE
or O
fatigue B-NonOSE_AE
. O

5.9 O
Peripheral O
Neuropathy O
SABRIL O
causes O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
adults O
. O

Pediatric O
clinical O
trials O
were O
not O
designed O
to O
assess O
symptoms O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
, O
but O
observed O
incidence O
of O
symptoms O
based O
on O
pooled O
data O
from O
controlled O
pediatric O
studies O
appeared O
similar O
for O
pediatric O
patients O
on O
vigabatrin O
and O
placebo O
. O

In O
a O
pool O
of O
North O
American O
controlled O
and O
uncontrolled O
epilepsy B-Not_AE_Candidate
studies O
, O
4.2 O
% O
( O
19/457 O
) O
of O
SABRIL O
patients O
developed O
signs O
and/or O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

In O
the O
subset O
of O
North O
American O
placebo-controlled O
epilepsy O
trials O
, O
1.4 O
% O
( O
4/280 O
) O
of O
SABRIL O
treated O
patients O
and O
no O
( O
0/188 O
) O
placebo O
patients O
developed O
signs O
and/or O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Initial O
manifestations O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
these O
trials O
included O
, O
in O
some O
combination O
, O
symptoms O
of O
numbness B-NonOSE_AE
or O
tingling O
in O
the O
toes I-NonOSE_AE
or O
feet O
, O
signs O
of O
reduced B-NonOSE_AE
distal I-NonOSE_AE
lower I-NonOSE_AE
limb I-NonOSE_AE
vibration I-NonOSE_AE
or O
position O
sensation O
, O
or O
progressive B-NonOSE_AE
loss I-NonOSE_AE
of I-NonOSE_AE
reflexes I-NonOSE_AE
, O
starting O
at O
the O
ankles O
. O

Clinical O
studies O
in O
the O
development O
program O
were O
not O
designed O
to O
investigate O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
systematically O
and O
did O
not O
include O
nerve O
conduction O
studies O
, O
quantitative O
sensory O
testing O
, O
or O
skin O
or O
nerve O
biopsy O
. O

There O
is O
insufficient O
evidence O
to O
determine O
if O
development O
of O
these O
signs O
and O
symptoms O
were O
related O
to O
duration O
of O
SABRIL O
treatment O
, O
cumulative O
dose O
, O
or O
if O
the O
findings O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
were O
completely O
reversible O
upon O
discontinuation O
of O
SABRIL O
. O

5.10 O
Weight O
Gain O
SABRIL O
causes O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
in O
adult O
and O
pediatric O
patients O
. O

Data O
pooled O
from O
randomized O
controlled O
trials O
in O
adults O
found O
that O
17 O
% O
( O
77/443 O
) O
of O
SABRIL O
patients O
versus O
8 O
% O
( O
22/275 O
) O
of O
placebo O
patients O
gained B-OSE_Labeled_AE
> O
=7 O
% O
of O
baseline O
body O
weight I-OSE_Labeled_AE
. O

In O
these O
same O
trials O
, O
the O
mean O
weight O
change O
among O
SABRIL O
patients O
was O
3.5 O
kg O
compared O
to O
1.6 O
kg O
for O
placebo O
patients O
. O

Data O
pooled O
from O
randomized O
controlled O
trials O
in O
pediatric O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
found O
that O
47 O
% O
( O
77/163 O
) O
of O
SABRIL O
patients O
versus O
19 O
% O
( O
19/102 O
) O
of O
placebo O
patients O
gained B-OSE_Labeled_AE
> O
=7 O
% O
of O
baseline O
body O
weight I-OSE_Labeled_AE
. O

In O
all O
epilepsy B-Not_AE_Candidate
trials O
, O
0.6 O
% O
( O
31/4855 O
) O
of O
SABRIL O
patients O
discontinued O
for O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

The O
long O
term O
effects O
of O
SABRIL O
related O
weight B-NonOSE_AE
gain I-NonOSE_AE
are O
not O
known O
. O

Weight B-NonOSE_AE
gain I-NonOSE_AE
was O
not O
related O
to O
the O
occurrence O
of O
edema B-NonOSE_AE
. O

5.11 O
Edema O
SABRIL O
causes O
edema B-OSE_Labeled_AE
in O
adults O
. O

Pediatric O
clinical O
trials O
were O
not O
designed O
to O
assess O
edema B-NonOSE_AE
, O
but O
observed O
incidence O
of O
edema B-NonOSE_AE
based O
pooled O
data O
from O
controlled O
pediatric O
studies O
appeared O
similar O
for O
pediatric O
patients O
on O
vigabatrin O
and O
placebo O
. O

Pooled O
data O
from O
controlled O
trials O
demonstrated O
increased O
risk O
among O
SABRIL O
patients O
compared O
to O
placebo O
patients O
for O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
SABRIL O
2 O
% O
, O
placebo O
1 O
% O
) O
, O
and O
edema B-OSE_Labeled_AE
( O
SABRIL O
1 O
% O
, O
placebo O
0 O
% O
) O
. O

In O
these O
studies O
, O
one O
SABRIL O
and O
no O
placebo O
patients O
discontinued O
for O
an O
edema B-OSE_Labeled_AE
related O
AE O
. O

In O
adults O
, O
there O
was O
no O
apparent O
association O
between O
edema B-NonOSE_AE
and O
cardiovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
such O
as O
hypertension B-NonOSE_AE
or O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Edema B-NonOSE_AE
was O
not O
associated O
with O
laboratory B-NonOSE_AE
changes I-NonOSE_AE
suggestive O
of O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal O
or O
hepatic I-NonOSE_AE
function I-NonOSE_AE
. O

